1. Weller TH, Macaulay JC, Craig JM, Wirth P. Isolation of intranuclear inclusion producing agents from infants with illnesses resembling cytomegalic inclusion disease. Proc Soc Exp Biol Med.
1957; 94:4-12.
2. Rubin RH, Cosimi AB, Tolkoff-Rubin NE, et al.: Infectious disease syndromes attributable to cytomegalovirus and their significance among renal transplant recipients. Transplantation 1977;
24: pp. 458-464.
3. Myers JD, Spencer HC, Watts JC, et al.: Cytomegalovirus pneumonia after human marrow transplantation. Ann Intern Med 1975; 82: pp. 181-188.
4. Spector SA, Hsia K, Crager M, et al.: Cytomegalovirus (CMV) DNA load is an independent predictor of CMV disease and survival in advanced AIDS . J Virol 1999; 73: pp. 7027-7030.
5. Britt W. Manifestations of human cytomegalovirus infection: proposed mechanisms of acute and chronic disease. Curr Top Microbiol Immunol. 2008;325:417-70.
6. Nikitskaya E, Lebedeva A, Ivanova O, Maryukhnich E, Shpektor A, Grivel JC, et al. Cytomegalovirus-productive infection is associated with acute coronary syndrome. J Am Heart Assoc.
2016;5(6):e003759.
7. Vanheusden M, Stinissen P, ’t Hart BA, Hellings N. Cytomegalovirus: a culprit or protector in multiple sclerosis? Trends Mol Med. 2015;21(1):16-23.
8. Vanheusden M, Broux B, Welten SP, Peeters LM, Panagioti E, Van Wijmeersch B, et al. Cytomegalovirus infection exacerbates autoimmune mediated neuroinflammation. Sci Rep. 2017;7:663.
9. Kotton CN, Hirsch MS. Cytomegalovirus and human herpesvirus types 6, 7, and 8. In: Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J, Holland SM, Langford CA, editors.
Harrison’s Principles of Internal Medicine. 22nd ed. New York: McGraw-Hill; 2025. p.1/9.
10. Leruez-Ville M, Piret J, Boeckh M. Human cytomegalovirus: from biology to therapy. Clin Microbiol Rev. 2023;36(1):e00221-22.
11. Griffiths PD, Emery VC. Cytomegalovirus. In: Bennett JE, Dolin R, Blaser MJ, editors. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. 9th ed. Philadelphia:
Elsevier; 2020. p. 1734-1754.
12. Baruah V, Krishna BA, Kelly MC, Qi X, O’Connor CM. Inhibition of MAPK signaling suppresses cytomegalovirus reactivation in CD34⁺ Kasumi-3 cells. Antiviral Res. 2025; 238:106169.
13. Reeves MB. Chromatin-mediated regulation of cytomegalovirus gene expression. Virus Res. 2020;281:197939.
14. Yu M. microRNA, a subtle indicator of human cytomegalovirus latency and reactivation in CD34⁺ progenitor cells. Vaccines. 2022;10(2):144.
15. Purandare N, Goodrum F. Human cytomegalovirus reprograms host metabolism. Viruses. 2023;15(2):377.
16. Biolatti M, Dell’Oste V, De Andrea M, Landolfo S. The human cytomegalovirus tegument protein pp65 (pUL83) dampens type I interferon production by inactivating the DNA sensor cGAS
without affecting STING. J Virol. 2018;92(2):e01774-17.
17. Rückert T, et al. Clonal expansion and epigenetic inheritance of long-lived adaptive NK cells in response to human cytomegalovirus infection. Nat Immunol. 2022;23:1205–1217.
18. Shen Y, Zhang L, Xue X, Feng S. Molecular mechanisms and targets underlying immune evasion by human cytomegalovirus. J Microbiol Immunol Infect. 2025; S1684-1182.
19. Zuhair M, Smit GSA, Wallis G, Jabbar F, Smith C, Devleesschauwer B, Griffiths P. Estimation of the worldwide seroprevalence of cytomegalovirus: A systematic review and meta-analysis. Rev
Med Virol. 2019;29(3):e2034.
20. Kahraman Kilbaş EP, Çiftçi İH, Kilbaş I, Toptan H. Seroprevalence of TORCH Viral Agents in Pregnant Women in Turkey: Systematic Review and Meta-Analysis. Pathogens. 2025;14(1):37.
21. Satılmış A, Güra A, Ongun H, Mendilcioğlu İ, Çolak D, Oygür N. CMV seroconversion in pregnants and the incidence of congenital CMV infection. Turk J Pediatr. 2007;49(1):30-36.
22. Uysal A, Taner CE, Cüce M, Atalay S, Göl B, Köse S, Uysal F. Cytomegalovirus and rubella seroprevalence in pregnant women in Izmir/Turkey: follow-up and results of pregnancy outcome.
Arch Gynecol Obstet. 2012;286(3):605-608.
23. Bahçeci İ, Karaca E, Duran ÖF, Aksoy D, İbik YE, Kırcı UB. Seroprevalence of Toxoplasma, Rubella and Cytomegalovirus in Women of Fertility Age in Our Region. Turkiye Parazitol Derg.
2023;47(1):11-15.
24. Ssentongo P, Wang M, Parrado AR, et al. Global and regional prevalence of congenital cytomegalovirus infection: a systematic review and meta-analysis. JAMA Netw Open. 2021;4(8):e2120734.
25. Şahiner F, Cekmez F, Cetinkaya M, et al. Congenital cytomegalovirus infection in Turkey: birth prevalence among live-born infants. Infect Dis (Lond). 2015;47(7):465–471.
26. Eres Sarıtaş Z, Peker BO, Çolak D, et al. Congenital cytomegalovirus infection cases and follow-up findings in Antalya, Turkey. Marmara Med J. 2023;36(3):290–296.
27. Ziemann M, Thiele T: Transfusion-transmitted CMV infection- current knowledge and future perspectives . Transfus Med 2017; 27: pp. 238-248.
28. Griffiths, P., Reeves, M. Pathogenesis of human cytomegalovirus in the immunocompromised host. Nat Rev Microbiol. 2021; (19): 759–773.
29. Peggs KS, Verfuerth S, Mackinnon S. Adoptive T-cell therapy for cytomegalovirus. Lancet Infect Dis. 2011;11(9):725–36.
30. Schattner A. The Wide Spectrum of Presentations of Cytomegalovirus Infection in Immunocompetent Hosts: An Exhaustive Narrative Review. Pathogens. 2024 Aug 7;13(8):667.
31. Imlay H, Limaye AP, et al. Current Understanding of Cytomegalovirus Reactivation in Critical Illness. J Infect Dis. 2020;221(Suppl 1):S94–S102.
32. Wang Y, Aggarwal P, Liu X, et al.: Antiviral treatment for colonic cytomegalovirus infection in ulcerative colitis patients significantly improved their surgery free survival . J Clin Gastroenterol
2018; 52: pp. e27-e31.
33. Emery VC, Asher K, Sanjuan Cde J: Importance of the cytomegalovirus seropositive recipient as a contributor to disease burden after solid organ transplantation . J Clin Virol 2012; 54: pp.
125-129.
34. Lee H, Park KH, Ryu JH, et al.: Cytomegalovirus (CMV) immune monitoring with ELISPOT and QuantiFERON-CMV assay in seropositive kidney transplant recipients . PLoS ONE 2017;
12: pp.
35. Advances in Managing Infections in Lung Transplantation: A Review. OBM Transplantation. 2024;8(2):215.
36. Razonable RR, Humar A. Cytomegalovirus in solid organ transplant recipients-Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice. Clin
Transplant. 2019 Sep;33(9):e13512.
37. Kotton CN, Kumar D, Manuel O, Chou S, Hayden RT, Danziger-Isakov L, Asberg A, Tedesco-Silva H, Humar A; Transplantation Society International CMV Consensus Group. The Fourth
International Consensus Guidelines on the Management of Cytomegalovirus in Solid Organ Transplantation. Transplantation. 2025 Jul 1;109(7):1066-1110.
38. Lee F, Nair V, Chih S. Cardiac allograft vasculopathy: Insights on pathogenesis and therapy. Clin Transplant. 2020 Mar;34(3):e13794.
39. Ishikawa S, Tasaki M, Saito K, Nakagawa Y, Ikeda M, Takahashi K, Tomita Y. Long-term CMV monitoring and chronic rejection in renal transplant recipients. Front Cell Infect Microbiol.
2023 Jun 13;13:1190794.
40. Udomkarnjananun S, Iampenkhae K. Pathological Approach to Kidney Allograft Infection. Biomedicines. 2023; 11(7):1902.
41. Teira P, Battiwalla M, Ramanathan M, et al.: Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis . Blood
2016; 127: pp. 2427-2438.
42. George B, Pati N, Gilroy N, et al.: Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell
transplantation in the era of surveillance and preemptive therapy . Transpl Infect Dis 2010; 12: pp. 322-329.
43. Allaw F, Haddad SF, Zakhour J, Kanj SS. Management of cytomegalovirus infection in allogeneic hematopoietic stem cell transplants. Int J Antimicrob Agents. 2023 Aug;62(2):106860.
44. Türk Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Uzmanlık Derneği (EKMUD) Sitomegalovirüs Tanı, Tedavi Uzlaşı Raporu 2020 (erişim 2025 Eki 25). Erişim adresi: https://www.ekmud.
org.tr/files/Rehberler/ekmudrehberler/sitomegalovirus-tani-tedavi-uzlasi-raporu.pdf
45. Stagno S, Pass RF, Cloud G, et al.: Primary cytomegalovirus infection in pregnancy. Incidence, transmission to fetus, and clinical outcome. JAMA 1986; 256: pp. 1904-1908.
46. Britt WJ: Congenital HCMV infection and the enigma of maternal immunity. J Virol 2017; 91: pp. e02392.
47. Stagno S, Pass RF, Dworsky ME, et al.: Congenital cytomegalovirus infection: the relative importance of primary and recurrent maternal infection. N Engl J Med 1982; 306: pp. 945-949.
48. Manicklal S, Emery VC, Lazzarotto T, Boppana SB, Gupta RK. The “silent” global burden of congenital cytomegalovirus. Clin Microbiol Rev. 2013;26(1):86-102.
49. Mussi-Pinhata MM, Yamamoto AY, Britto MMM. Birth prevalence and natural history of congenital cytomegalovirus (CMV) infection in a highly seroimmune population. Clin Infect Dis
2009;49:522-8.
50. Zeytinoğlu A, Terek D, Arslan A, Erensoy S, Altun Köroğlu Ö, Bozdemir T, Yalaz M, Ergör SN, Öğüt MF, Kültürsay N. Investigation of congenital CMV infection with the presence of CMV
DNA in saliva samples of new born babies. Mikrobiyol Bul. 2019;53(1):53-60.
51. Leber AL. Maternal and congenital human cytomegalovirus infection: laboratory testing for detection and diagnosis. J Clin Microbiol. 2024 Apr 10;62(4):e0031323. doi: 10.1128/jcm.00313-
23. Epub 2024 Feb 23. Erratum in: J Clin Microbiol. 2024 Sep 11;62(9):e0116424. doi: 10.1128/jcm.01164-24.
52. Dreher AM, Arora N, Fowler KB, Novak Z, Britt WJ, Boppana SB, Ross SA. Spectrum of disease and outcome in children with symptomatic congenital cytomegalovirus infection. J Pediatr.
2014 Apr;164(4):855-9.
53. de Vries LS, Gunardi H, Barth PG, et al.: The spectrum of cranial ultrasound and magnetic resonance imaging abnormalities in congenital cytomegalovirus infection . Neuropediatrics 2004;
35: pp. 113-119.
54. Morton CC, Nance WE: Newborn hearing screening–a silent revolution . N Engl J Med 2006; 354: pp. 2151-2164.
55. Cradeur A, Jackson A, Ware E, Fourrier TL, Mankekar G. Congenital Cytomegalovirus (cCMV) Infection as a Leading Cause of Pediatric Hearing Loss: Review. Children (Basel). 2025 May
8; 12(5): 613.
56. American Academy of Pediatrics. Cytomegalovirus infection. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30th, Kimberlin DW (Ed), American Academy of Pediat-
rics, Elk Grove Village, IL 2015. p.317.
57. Fryer JF, Heath AB, Minor PD: A collaborative study to establish the 1st WHO International Standard for human cytomegalovirus for nucleic acid amplification technology . Biologicals 2016;
44: pp. 242-251.
58. Moon SM, Sung H, Kim MN, et al.: Diagnostic yield of the cytomegalovirus (CMV) antigenemia assay and clinical features in solid organ transplant recipients and hematopoietic stem cell
transplant recipients with CMV pneumonia. Transpl Infect Dis 2012; 14: pp. 192-197.
59. Ljungman P, Alain S, Chemaly RF, Einsele H, Galaverna F, Hirsch HH, Sadowska-Klasa A, Navarro D, Styczynski J, de la Camara R. Recommendations from the 10th European Conference on
Infections in Leukaemia for the management of cytomegalovirus in patients after allogeneic haematopoietic cell transplantation and other T-cell-engaging therapies. Lancet Infect Dis. 2025
Aug;25(8):e451-e462.
60. Ross SA, Novak Z, Pati S, Boppana SB. Overview of the diagnosis of cytomegalovirus infection. Infect Disord Drug Targets. 2011 Oct;11(5):466-74. doi: 10.2174/187152611797636703.
61. Avery RK, Alain S, Alexander BD, Blumberg EA, Chemaly RF, Cordonnier C, et al. Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: results from
a phase 3 randomized clinical trial. Lancet Infect Dis. 2022;22(5): 690–701.
62. Papanicolaou GA, Avery RK, Cordonnier C, Duarte RF, Haider S, Maertens J, Peggs KS, Solano C, Young JH, Fournier M, Murray RA, Wu J, Winston DJ; AURORA Trial Investigators. Tre-
atment for First Cytomegalovirus Infection Post-Hematopoietic Cell Transplant in the AURORA Trial: A Multicenter, Double-Blind, Randomized, Phase 3 Trial Comparing Maribavir With
Valganciclovir. Clin Infect Dis. 2024 Mar 20;78(3):562-572. doi: 10.1093/cid/ciad709. Erratum in: Clin Infect Dis. 2024 Sep 26;79(3):803.
63. Russo D, Schmitt M, Pilorge S, Stelljes M, Kawakita T, Teal VL, Haber B, Bopp C, Dadwal SS, Badshah C. Efficacy and safety of extended duration letermovir prophylaxis in recipients
of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematol. 2024 Fe-
b;11(2):e127-e135.
64. Limaye AP, Budde K, Humar A, Vincenti F, Kuypers DRJ, Carroll RP, Stauffer N, Murata Y, Strizki JM, Teal VL, Gilbert CL, Haber BA. Letermovir vs Valganciclovir for Prophylaxis of Cyto-
megalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical Trial. JAMA. 2023 Jul 3;330(1):33-42.
65. Goodrich JM, Mori M, Gleaves CA, et al.: Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation . N Engl J Med 1991; 325: pp.
1601-1607.
66. Girmenia C, Lazzarotto T, Martino M, Bonifazi F, Baldanti F, Clerici P, Citterio F, De Carlis L, Barosi G, Grossi PA. Management of Cytomegalovirus Infection in Allogeneic Hematopoietic
Stem Cell and in Solid Organ Transplantation: Updated Recommendations by the GITMO, SITO, SIMIT, and AMCLI Italian Societies. Clin Transplant. 2025 Aug;39(8):e70255.
67. Hu X, Karthigeyan KP, Herbek S, Valencia SM, Jenks JA, Webster H, Miller IG, Connors M, Pollara J, Andy C, Gerber LM, Walter EB, Edwards KM, Bernstein DI, Hou J, Koch M, Panther L,
Carfi A, Wu K, Permar SR. Human Cytomegalovirus mRNA-1647 Vaccine Candidate Elicits Potent and Broad Neutralization and Higher Antibody-Dependent Cellular Cytotoxicity Respon-
ses Than the gB/MF59 Vaccine. J Infect Dis. 2024 Aug 16;230(2):455-466.
68. Overview of mRNA-1647: Investigational CMV Vaccine
69. Valencia SM, Rochat E, Harnois MJ, Dennis M, Webster HS, Hora B, Kumar A, Wang HS, Li L, Freed D, Zhang N, An Z, Wang D, Permar SR. Vaccination with a replication-defective cyto-
megalovirus vaccine elicits a glycoprotein B-specific monoclonal antibody repertoire distinct from natural infection. NPJ Vaccines. 2023 Oct 10;8(1):154.
70. Walti CS, Khanna N, Avery RK, Helanterä I. New treatment options for refractory/resistant CMV infection. Transpl Int. 2023;36:11785.
71. Ma C, Chen P, Du J, Wang L, Lu N, Sun J, Qilong X, Wang Y, Dou L, Liu DH. Adoptive transfer of CMV-specific TCR-T cells for the treatment of CMV infection after haploidentical hemato-
poietic stem cell transplantation. J Immunother Cancer. 2024 Jan 6;12(1):e007735.
72. Fung JST, Wright RC, Bharaj DK, Alghamdi A, Hesson D, Delisle JS, Schweitzer L, Avery RK, Belga S. Virus-specific T-cell therapy for prophylaxis and treatment of cytomegalovirus infections
after transplantation: a scoping review. Clin Infect Dis. 2025 May 6:ciaf232.